Cencora, Inc. $COR Shares Purchased by Clark Capital Management Group Inc.

Clark Capital Management Group Inc. boosted its position in Cencora, Inc. (NYSE:CORFree Report) by 0.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 253,639 shares of the company’s stock after purchasing an additional 2,172 shares during the period. Clark Capital Management Group Inc. owned about 0.13% of Cencora worth $85,666,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in Cencora by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 23,617,117 shares of the company’s stock valued at $7,976,681,000 after purchasing an additional 221,570 shares during the period. State Street Corp lifted its position in Cencora by 1.3% in the fourth quarter. State Street Corp now owns 9,305,507 shares of the company’s stock valued at $3,142,935,000 after purchasing an additional 115,191 shares during the period. Geode Capital Management LLC lifted its position in Cencora by 3.2% in the fourth quarter. Geode Capital Management LLC now owns 5,459,476 shares of the company’s stock valued at $1,843,268,000 after purchasing an additional 169,055 shares during the period. JPMorgan Chase & Co. lifted its position in Cencora by 6.5% in the fourth quarter. JPMorgan Chase & Co. now owns 4,982,557 shares of the company’s stock valued at $1,682,859,000 after purchasing an additional 304,760 shares during the period. Finally, Boston Partners lifted its position in Cencora by 2.0% in the third quarter. Boston Partners now owns 4,509,165 shares of the company’s stock valued at $1,409,152,000 after purchasing an additional 89,506 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Trading Down 0.1%

Shares of COR opened at $281.22 on Wednesday. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. The firm has a 50 day simple moving average of $287.49 and a 200-day simple moving average of $326.05. Cencora, Inc. has a 1-year low of $244.82 and a 1-year high of $377.54. The stock has a market cap of $54.71 billion, a price-to-earnings ratio of 21.57, a price-to-earnings-growth ratio of 1.52 and a beta of 0.59.

Cencora (NYSE:CORGet Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The business had revenue of $78.36 billion for the quarter, compared to analysts’ expectations of $81.09 billion. During the same period last year, the business earned $4.42 earnings per share. The company’s revenue for the quarter was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Equities analysts forecast that Cencora, Inc. will post 17.79 EPS for the current fiscal year.

Cencora declared that its Board of Directors has authorized a share buyback program on Thursday, May 21st that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the company to purchase up to 3.9% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s board of directors believes its stock is undervalued.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were paid a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend was Friday, May 15th. Cencora’s dividend payout ratio (DPR) is 18.40%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on COR shares. Citigroup reduced their price objective on shares of Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Weiss Ratings downgraded shares of Cencora from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, May 22nd. Robert W. Baird reduced their price target on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. William Blair assumed coverage on shares of Cencora in a research report on Tuesday, April 28th. They set a “market perform” rating for the company. Finally, Leerink Partners reiterated an “outperform” rating on shares of Cencora in a research report on Tuesday, March 17th. Twelve investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, Cencora has a consensus rating of “Moderate Buy” and a consensus price target of $374.00.

Get Our Latest Stock Analysis on COR

Cencora Company Profile

(Free Report)

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

See Also

Institutional Ownership by Quarter for Cencora (NYSE:COR)

Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.